Copenhagen-based Pcovery is looking to fight invasive Fungal Infections

08/07/2016 - 2 minutes

After another visit to the United Kingdom, we ‘Brexit’ towards other geographies! We’re crossing the English Channel back to the continent and go further up to Denmark. This week, in Copenhagen, we’re visiting Pcovery, our Biotech of the Week.

pcovery_logo_biotech_weekCity: Copenhagen (Denmark)

Founded: 2009

Employees: 6

Financial Data: €7.5M Total Raised (as of 12/2015)

CEO: Casper Tind Hansen

Related Content

pcovery biotech


Pcovery is a drug discovery company focused on the anti-fungal area. It combines expertise within protein structure, medicinal chemistry, drug discovery and -development, and pathogenic fungal infections to create a novel class of anti-fungals to treat serious invasive fungal infections.

There is a strong need for anti-fungals, given the infection rates of common fungi, from Candida (yeast) to other more serious infections (e.g. from Aspergillus types) is still so high – particularly in the immuno-compromised.

Its lead development project focuses on targeting a novel membrane protein found in the fungal cell membrane.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member